Login / Signup

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer.

Gaia GriguoloMaria Vittoria DieciLaia ParéFederica MigliettaDaniele Giulio GeneraliAntonio FrassoldatiLuigi CavannaGiancarlo BisagniFrancesco GiottaEnrico TagliaficoKatia CagossiGuido FicarraAleix PratPierfranco ConteValentina Guarneri
Published in: NPJ breast cancer (2021)
Little is known regarding the interaction between immune microenvironment and tumor biology in hormone receptor (HR)+/HER2- breast cancer (BC). We here assess pretreatment gene-expression data from 66 HR+/HER2- early BCs from the LETLOB trial and show that non-luminal tumors (HER2-enriched, Basal-like) present higher tumor-infiltrating lymphocyte levels than luminal tumors. Moreover, significant differences in immune infiltrate composition, assessed by CIBERSORT, were observed: non-luminal tumors showed a more proinflammatory antitumor immune infiltrate composition than luminal ones.
Keyphrases
  • gene expression
  • stem cells
  • clinical trial
  • dna methylation
  • randomized controlled trial
  • machine learning
  • electronic health record
  • artificial intelligence
  • phase ii
  • young adults
  • double blind